Show results for
Refine by
Locations
- USA
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District Of Columbia
- Florida
- Georgia (Us)
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Cancer Genetic Equipment Supplied In Usa
31 equipment items found
by:Acuamark Diagnostics based inNew York, NEW YORK (USA)
The vast majority of cancer cases are detected at stage III or beyond, resulting in poor cancer survival of ~50% in the aggregate. Cancer cases are forecasted to reach 25M per year over the next two decades, causing deaths to rise to 13M per year (worldwide). Annually, the worldwide economic impact of cancer is estimated by the WHO at $1.2 trillion. ...
by:Castle Biosciences, Inc. based inFriendswood, TEXAS (USA)
Our DecisionDx-UMSeq is a 7-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to uveal melanoma. Researchers believe that identifying mutations in tumor genes may someday help guide treatment decisions. Because the amount of tumor biopsy tissue is limited, it is important to gain as much information as possible about a uveal melanoma tumor from a single ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Pelabresib (CPI-0610) is an investigational selective small-molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain (BET) proteins to decrease the expression of abnormally expressed genes in cancer. The compound has demonstrated a wide therapeutic window, with activity seen at a 48 mg dose in a lymphoma study and with a maximum ...
Manufactured by:Veracyte, Inc. based inSouth San Francisco, CALIFORNIA (USA)
Revealing cancer molecular subtype to inform treatment decisions. Decipher Bladder is a genomic test that measures the molecular profile of bladder cancer using gene expression analysis from transurethral resected bladder tumor specimens. The test was developed for bladder cancer patients with high-grade non-muscle-invasive disease who are being considered for treatment and patients with ...
Manufactured by:SEngine Precision Medicine based inSeattle, WASHINGTON (USA)
Guiding drug discovery with proprietary high throughput 3D patient cell technology and genomics will drastically increase the success of novel drug candidates and directly result in faster development at reduced costs. SEngine Precision Medicine’s innovative approach brings diagnostics, drug discovery and proprietary algorithms together with our patient-derived 3D tumor organoids to ...
Manufactured by:EntroGen, Inc. based inWoodland Hills, CALIFORNIA (USA)
The KRAS gene encodes a small GTPase that plays a key role in transducing signals from the epidermal growth factor receptor (EGFR) to downstream effectors. KRAS mutations have been commonly found in several types of human malignancies, such as metastatic colorectal cancer (mCRC), lung adenocarcinoma and thyroid cancer. The most common mutations are found in codons 12, 13 and 61. Several studies ...
Manufactured by:EntroGen, Inc. based inWoodland Hills, CALIFORNIA (USA)
EntroGen RNA Fusion Gene Panel is a complete next generation sequencing (NGS) solution for detecting 307 clinically relevant fusions over 23 genes. ...
by:Psychē Systems Corporation based inHopkinton, MASSACHUSETTS (USA)
No two people’s bodies are exactly the same, so it stands to reason that people will react to medicines and treatments in different ways. While medical treatments can have broad, overall positive results, those results become varied when you examine the results in individual people and even in specific populations. That’s where precision medicine comes in. Precision medicine is the ...
Manufactured by:Veracyte, Inc. based inSouth San Francisco, CALIFORNIA (USA)
Reducing Unnecessary Surgeries and Informing Treatment Decisions in Thyroid Cancer Diagnosis. The Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas (XA) provide physicians with a comprehensive solution for a complex landscape in thyroid cancer diagnosis and individualization of care. The combined offering enables physicians to answer multiple clinical questions for their thyroid ...
Manufactured by:Jubilant Therapeutics Inc. based inBedminster, NEW JERSEY (USA)
Strong scientific and clinical rationale for LSD1/HDAC6 inhibition in haematological and solid ...
Manufactured by:IDT Biologika based inDessau-Rosslau, GERMANY
IDT Biologika is a leading viral vector CDMO with an exceptional track record in biologics manufacturing, including expertise with live viral agents. This makes us well-positioned to support the rapid growth in gene therapy and immunotherapeutics markets and the huge demand for transformative viral ...
by:Natera, Inc. based inAustin, TEXAS (USA)
Support treatment decisions with comprehensive tumor profiling. Gain deep insight into the tumor’s genomic alterations and oncology biomarkers with Altera. The detailed sequencing report includes FDA-approved treatments, novel treatment approaches and ongoing clinical trials targeting found mutations. Unlike any other tumor profiling assay, Altera also enables molecular residual disease ...
Manufactured by:GeneCentric Therapeutics, Inc. based inDurham, NORTH CAROLINA (USA)
Pancreatic Cancer is the 11th most common cancer type with an estimated 55,000 new cases in the US in 2018, according to the United States National Cancer Institute. While it represents three percent of all cancers, pancreatic cancer is one of the most lethal as it is so difficult to detect in early stages, accounting for seven percent of all cancer deaths and carrying among the lowest five ...
Manufactured by:Tempus based inChicago, ILLINOIS (USA)
Providing risk-assessment for hereditary cancer syndromes for patients and their families. xG+ (extended hereditary cancers): Covers genes associated with multiple hereditary cancer types, including common hereditary cancers (breast, ovarian, colorectal, endometrial, prostate, pancreatic) and others (renal/urinary tract, gastric, melanoma, thyroid, endocrine, sarcomas, central nervous system, ...
by:Tesis Biosciences based inScottsdale, ARIZONA (USA)
CGx Testing is a preventative gene test that looks for specific inherited changes (mutations) in a person’s genetic make-up. Harmful mutations may increase a persons’ chance, or risk, of developing a disease such as cancer. These conditions are considered hereditary. Appropriate genetic testing may be used to determine an ...
Manufactured by:Kura Oncology, Inc. based inSan Diego, CALIFORNIA (USA)
With the advent of precision medicines that can target unique molecular or genetic features of a patient’s tumor, the field of oncology has a host of alternatives to one-size-fits-all treatments. This is a major advance over traditional chemotherapy, which can be as potent against healthy tissue as it is against cancer. ...
Manufactured by:Grail, Inc. based inMenlo Park, CALIFORNIA (USA)
GRAIL is poised to detect cancer early by combining high-intensity sequencing of unprecedented breadth and depth with the techniques of modern data science. Through what we believe to be one of the largest clinical study programs ever pursued in genomic medicine, GRAIL is creating vast datasets to develop evidence supporting our ...
Manufactured by:Veracyte, Inc. based inSouth San Francisco, CALIFORNIA (USA)
Using prognostic information to inform next steps in patient care. The Prosigna Breast Cancer Prognostic Gene Signature Assay uses advanced genomic technology to inform next steps for patients with early-stage breast cancer, based on the genomic make-up of their disease. The test analyzes the activity of 50 genes known as the PAM50 gene signature, along with clinical-pathological features, and ...
Manufactured by:EntroGen, Inc. based inWoodland Hills, CALIFORNIA (USA)
The KRAS gene encodes a small GTPase that plays a key role in transducing signals from the epidermal growth factor receptor (EGFR) to downstream effectors. KRAS mutations have been commonly found in several types of human malignancies, such as metastatic colorectal cancer (mCRC), lung adenocarcinoma and thyroid cancer. The most common mutations are found in codons 12, 13 and 61. Several studies ...
Manufactured by:Manzanita Pharmaceuticals, Inc. based inWoodside, CALIFORNIA (USA)
Nervelight™, a topical, intraoperative nerve imaging agent that is selective for at-risk nerve tissue in cancer ...